Last night Luke Timmerman of Xconomy posted a nice article on the formation of a new Seattle startup, Juno Therapeutics, which aims to develop the chimeric antigen receptor therapy (CART) based on autologous T cells developed by Memorial Sloan Kettering (MSK) in New York, Fred Hutchinson Cancer Center (FHCC) and the Seattle Children’s Hospital, both in Seattle.

Juno secured $120M in Series A funding, which is pretty good for a two month old startup and shows how much excitement there is for this exciting technology.

How does this new development impact the CART landscape and in particular, the U Penn and Novartis partnership?

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. You are NOT PERMITTED to share access or copies of posts. If you wish to purchase a CORPORATE or MULTI-USER license or want to be able to share content PLEASE CONTACT US to purchase this. Please read the terms of use before purchasing & if you work in PR, Communications or for an agency, the guidance within it. Rates may change without notice and are non-refundable.